Shopping Cart
Remove All
Your shopping cart is currently empty
Ac2-26, an annexin A1 mimetic peptide, was able to attenuate renal inflammatory injury in a diabetic mouse model through inhibition of p38MAPK/NF-κB, as well as sepsis-induced cardiomyocyte apoptosis through the LXA4/PI3K/AKT signalling pathway, and hepatic ischaemia-reperfusion injury in mice by modulating IL-22/IL-22R1/STAT3 signalling pathway.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | - | In Stock | |
| 5 mg | $123 | - | In Stock | |
| 10 mg | $197 | - | In Stock | |
| 25 mg | $348 | - | In Stock | |
| 50 mg | $538 | - | In Stock |
| Description | Ac2-26, an annexin A1 mimetic peptide, was able to attenuate renal inflammatory injury in a diabetic mouse model through inhibition of p38MAPK/NF-κB, as well as sepsis-induced cardiomyocyte apoptosis through the LXA4/PI3K/AKT signalling pathway, and hepatic ischaemia-reperfusion injury in mice by modulating IL-22/IL-22R1/STAT3 signalling pathway. |
| In vitro | Ac2-26 (1 μM, 48 h) significantly reduced cardiomyocyte death under simulated ischemic conditions[1]. |
| In vivo | In mice subjected to ischemia-reperfusion injury, Ac2-26 (1 mg/kg, i.v., just before reperfusion) reduced myocardial necrosis, inflammation (48 h), and cardiac fibrosis/apoptosis (7 days). In myocardial infarction models, continuous subcutaneous delivery of Ac2-26 (1 mg/kg/day, via osmotic pump for 1 week) delayed early cardiac dysfunction at 1 week, though no additional benefit was observed at 4 weeks. |
| Molecular Weight | 3089.43 |
| Formula | C141H210N32O44S |
| Cas No. | 151988-33-9 |
| Smiles | C([C@@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC2=CC=C(O)C=C2)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(O)=O)=O)C(C)C)=O)[C@@H](C)O)=O)CCC(N)=O)=O)[C@@H](C)C)=O)=O)CCC(O)=O)=O)CCC(N)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CC(N)=O)=O)CCC(O)=O)=O)[C@H](CC)C)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC3=CC=CC=C3)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C)=O)C)=O)CCSC)=O)[C@@H](C)C)=O)CO)=O)CCC(O)=O)=O)=O)CC(C)C)=O)CCCCN)=O)CCC(N)=O)=O)C)=O)C=4C=5C(NC4)=CC=CC5 |
| Relative Density. | 1.327 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Sequence | Ac-Ala-Met-Val-Ser-Glu-Phe-Leu-Lys-Gln-Ala-Trp-Phe-Ile-Glu-Asn-Glu-Glu-Gln-Glu-Tyr-Val-Gln-Thr-Val-Lys |
| Sequence Short | Ac-AMVSEFLKQAWFIENEEQEYVQTVK |
| Storage | keep away from moisture | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | H2O: 5 mg/mL (1.62 mM), Sonication is recommended. | ||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (0.65 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||
Solution Preparation Table | |||||||||||
H2O
| |||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.